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Purpose: We investigated the association between cognitive impairment and chronic obstructive 
pulmonary disease (COPD), taking into account demographic and clinical variables evaluated 
during routine practice.
Patients and methods: We performed a post hoc analysis of a cross-sectional study that 
included subjects with stable COPD. Sociodemographic and clinical information was recorded 
using the Body mass index, airflow Obstruction, Dyspnea and Exacerbations index and the 
Charlson comorbidity index. Cognitive performance was studied by the mini-mental state 
examination, with a score less than 27 indicating clinical impairment. Depressive symptoms, 
physical activity, and quality of life (EuroQoL-5 dimensions and COPD Assessment Test) 
were also evaluated.
Results: The analysis included 940 subjects. The prevalence of cognitive impairment was 39.4%. 
Multivariate logistic regression models revealed that cognitive impairment was associated with 
educational level (odds ratio [OR] =0.096, 95% confidence interval [CI] =0.011–0.447) and 
poorer quality of life measured by the EuroQoL-5 dimensions social tariff (OR =0.967, 95% 
CI =0.950–0.983). When questionnaires were not included in the analysis, cognitive impair-
ment was associated with educational level (OR =0.063, 95% CI =0.010–0.934), number of 
exacerbations (OR =11.070, 95% CI =1.450–84.534), Body mass index, airflow Obstruction, 
Dyspnea and Exacerbations index score (OR =1.261, 95% CI =1.049–1.515), and the Charlson 
comorbidity index (OR =1.412, 95% CI =1.118–1.783).
Conclusion: Cognitive impairment is common in COPD and is associated with low educa-
tional level, higher disease severity, and increased comorbidity. This could have therapeutic 
implications for this population.
Keywords: chronic obstructive pulmonary disease, cognitive function, mini-mental state 
examination, depression, quality of life, comorbidity
Introduction
Chronic obstructive pulmonary disease (COPD) is characterized by progressive and 
partially reversible airflow limitation, and it is among the leading causes of mortality 
worldwide.1 COPD is a multicomponent disease, and patients present a range of 
comorbidities that have an impact on prognosis and may increase the risk of mortality.2 
The effects of COPD on respiratory and physical function have been well studied; 
moreover, due to the heavy burden of psychological disturbance, psychiatric morbidity, 
and disability in daily life, the mental health of COPD patients has received growing 
attention in recent years.3,4 The prevalence of cognitive impairment in patients with 
COPD ranges from 12% to 88%5 and is associated with depression, poor quality of 
life, which may affect patients’ ability to manage their disease, and reduced compli-
ance with medication and oxygen therapy,6,7 leading to adverse clinical outcomes.8–11 
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Therefore, cognitive function as well as emotional function 
are important aspects of the overall clinical care of patients 
with COPD.
It has been suggested that a multidimensional assess-
ment and personalized disease management approach could 
be an optimal strategy for addressing comorbidities, self-
management education, and risk factor modification in COPD 
patients.7 The early identification of cognitive dysfunction 
is critical if outcomes are to be improved in this population, 
and an understanding of the characteristics associated with 
a higher risk of cognitive impairment may assist health care 
professionals to address this challenge.
The primary aim of this study was to examine the cross-
sectional prevalence of cognitive impairment in an unselected 
population of COPD patients; the secondary objective was 
to determine the relationships between cognitive impairment 
and major demographic and clinical variables, such as lung 
function, depression, and quality of life.
Materials and methods
study design and sample
The present study is a post hoc analysis of a cross-sectional, 
observational study conducted in respiratory medicine depart-
ments and primary care centers in Spain.11 This study was 
aimed at examining the prevalence of depressive symptoms 
and moderate-to-severe depression in COPD and included 
ambulatory patients who were 40 years of age or older, 
with stable COPD (confirmed by postbronchodilator forced 
expiratory volume in 1 second/forced vital capacity ,70% 
and absence of exacerbations in the previous 3 months). All 
patients that completed the mini-mental state examination 
(MMSE) were included in this post hoc analysis. The study 
was approved by the Institutional Ethics Committee of the 
Hospital Clinic (Barcelona, Spain) and was conducted in 
accordance with the principles of the Declaration of Helsinki. 
Prior to participation, all patients signed written documenta-
tion that the informed consent process was completed.
study assessments
Investigators recorded patients’ sociodemographic data and 
clinical information on COPD severity using the Modified 
Medical Research Council Dyspnea scale12 and the Body 
mass index, airflow Obstruction, Dyspnea and Exacerbations 
(BODEx) index,13 comorbidity according to the Charlson 
index,14 exacerbations in the previous year, and treatment. 
Cognitive status was assessed by the MMSE,15,16 widely used 
to screen for cognitive impairment. This instrument explores 
spatial and temporal orientation, registration, attention, and 
calculation, recall, language, and visual construction in 
12 items and 30 questions. A correct answer to one question 
was given 1 score point (total from 0 to 30). A score of less 
than 27 indicated cognitive impairment.17
Depressive symptoms were measured using the short 
Beck Depression Inventory questionnaire.18,19 This tool is a 
13-item self-administered inventory that assesses affective, 
cognitive, motivational, and vegetative symptoms of depres-
sion. Items use a 4-point scale that ranges from 0 to 3 and 
a total score is calculated by adding up the item responses. 
An additional question was included about suicidal ideation 
and suicidal attempts.
Health-related quality of life was assessed by the generic 
EuroQoL-5 dimensions (EQ-5D) questionnaire and the spe-
cific COPD Assessment Test (CAT). The EQ-5D consists of 
a 5-item descriptive system (including mobility, self-care, 
usual activities, pain/discomfort, and anxiety/depression), 
with each item rated as no problems, some problems, or 
severe problems, and an overall health state score for the 
day of the assessment, measured on a visual analog scale 
(0–100; 100 represents best overall health).20 The CAT is 
a short, specific quality of life questionnaire for measuring 
the impact of COPD on the patient’s well-being and daily 
life. It consists of eight items, each presented as a 6-point 
semantic differential scale, providing a score out of 40, 
indicating the impact of the disease.21 We used the validated 
Spanish version of CAT.22 Physical activity was measured by 
asking patients how many minutes, on average, they walked 
every weekday, as previously described.23,24 Depending on 
their daily walking activity, patients were classified into 
three groups: patients who walked ,30 minutes, patients 
who walked between 30 and 60 minutes, and patients who 
walked $60 minutes.
statistical analysis
Continuous variables were expressed as the mean and the 
standard deviation. Categorical values were described as 
absolute and relative frequencies. Fisher’s exact test was used 
for comparisons of qualitative variables, with the Bonferroni 
correction for all pairwise comparisons. Student’s t-test was 
used to determine the relationship between qualitative vari-
ables by group. Odds ratio (OR) univariates were calculated 
by logistic regression to evaluate the different risks con-
templated in the study, including all demographic, clinical, 
and questionnaires variables. Only significant associations 
are shown in the Tables 2 and 3. After stepwise analysis, 
the various adjusted ORs were calculated using multivari-
ate logistic regression. The first model was developed with 
cognitive status as a dependent variable and all variables that 
showed a significant association with cognition in univariate 
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analysis as independent variables (model 1). A second model 
(model 2) excluded any variables derived from the use of the 
questionnaires from the independent variables. The objective 
of model 2 was to identify the factors associated with cogni-
tive impairment that could be identified in routine clinical 
practice without the administration of questionnaires.
All statistical tests were considered significant when 
P was ,0.05. Statistical analyses were performed using SAS 
version 9.1.3 Service Pack 3 software (SAS Institute Inc., 
Cary, NC, USA).
Results
sample characteristics and cognitive 
status
Of 1,273 screened patients, 333 had not had the MMSE eval-
uation and were excluded from the analysis. Both popula-
tions (excluded and included ones) were compared and their 
characteristics are described in Table 1. Included patients 
were predominantly male, with an age ranging from 40 to 
90 years. A total of 370 patients (39.4%) scored below the 
threshold of 27 for suspicion of mild cognitive impairment 
Table 1 Characteristics of all patients with and without cognitive impairment according to MMse scores
Variable Excluded patients Included patients MMSE ,27 MMSE $27 P-value
sex, males (n, %) 233 (73.1%)a 762 (81.6%) 299 (81.7%) 463 (81.5%) .0.99
age, years (mean, sD) 66.8 (9.4) 67.7 (10.0) 69.6 (9.5) 66.5 (10.1) ,0.001
Coexistence (n, %)
alone 55 (17.1%) 121 (13.0%) 50 (13.6%) 71 (12.5%) ,0.001b
With partner 212 (66.0%) 646 (69.2%) 224 (61.0%) 422 (74.4%)
With family 47 (14.6%) 141 (15.1%) 75 (20.4%) 66 (11.6%)
Institutionalized 1 (0.3%) 12 (1.3%) 8 (2.2%) 4 (0.7%)
With professional caregiver 6 (1.9%) 14 (1.5%) 10 (2.7%) 4 (0.7%)
educational level (n, %)
Basic literacy 47 (14.7%)a 74 (7.9%) 42 (11.4%) 32 (5.7%) ,0.001c
Primary level 190 (59.6%) 540 (57.9%) 251 (68.4%) 289 (51.1%)
secondary level 62 (19.4%) 193 (20.7%) 52 (14.2%) 141 (25.0%)
Completed university 20 (6.3%)a 125 (13.4%) 22 (6.0%) 103 (18.2%)
COPD duration (mean, sD) 10.4 (6.4) 11.6 (7.7) 12.9 (8.0) 10.8 (7.4) ,0.001
active smoker (n, %) 77 (25.8%) 206 (22.4%) 66 (18.4%) 140 (25.0%) .0.99
Pack-years (mean, sD) 37.1 (20.4) 39.5 (21.8) 42.3 (24.8) 37.7 (19.4) 0.002
BMI (mean, sD) 27.5 (4.7) 27.8 (4.7) 27.9 (4.7) 27.7 (4.7) 0.52
Postbronchodilator spirometry (mean, sD)
FVC, ml 2,945 (977) 3,046 (977) 2,912 (922) 3,132 (1,001) 0.001
FVC, % 65.4 (21.2)a 71.0 (17.0) 71.3 (15.8) 70.8 (17.70) 0.55
FeV1, ml 1,805 (846) 1,886 (852) 1,778 (767) 1,957 (897) 0.002
FeV1, % 54.4 (21.0) 55.2 (17.8) 55.7 (17.9) 54.9 (17.7) 0.59
FeV1/FVC 56.6 (16.0) 58.5 (20.9) 57.2 (13.8) 59.4 (24.4) 0.13
Cough (n, %) 264 (85.7%) 770 (83.2%) 322 (89.7%) 448 (79.1%) ,0.001
expectoration (n, %) 233 (78.4%) 669 (73.0%) 286 (79.7%) 383 (68.7%) ,0.001
Dyspnea, (n, %) 296 (94.0%) 891 (95.0%) 359 (97.5%) 532 (93.3%) 0.003
mMrC dyspnea score (mean, sD) 2.8 (0.9) 2.8 (0.9) 3.1 (0.9) 2.6 (0.9) ,0.001
Patient with exacerbations (n, %) 265 (79.6%)a 808 (86.0%) 351 (94.9%) 457 (80.2%) ,0.001
number of hospital-treated exacerbations
(emergency + admission) (mean, sD)
1.3 (0.5)a 1.4 (2.2) 1.8 (2.7) 1.0 (1.5) ,0.001
Oxygen therapy at home, (n, %) 65 (23.0%) 204 (23.4%) 130 (37.0%) 74 (14.2%) ,0.001
BODex (mean, sD) 2.7 (1.8) 2.8 (1.9) 3.3 (1.8) 2.4 (1.9) ,0.001
Charlson comorbidity index (mean, sD) 1.3 (1.4)a 1.4 (1.4) 1.6 (1.5) 1.0 (0.6) ,0.001
BDI score (mean, sD) 9.3 (6.1) 9.0 (6.5) 11.7 (6.4) 7.2 (5.7) ,0.001
suicidal ideation (n, %) 29 (9.4%) 123 (13.1%) 78 (21.2%) 45 (7.9%) ,0.001
health status according to eQ-5D (mean, sD) 57.9 (17.1) 57.4 (19.2) 52.4 (18.2) 60.5 (19.2) ,0.001
social tariff eQ-5D (mean, sD) 0.6 (0.2) 0.6 (0.2) 0.5 (0.2) 0.7 (0.2) ,0.001
CaT score (mean, sD) 21.6 (7.3) 21.6 (8.6) 25.2 (6.9) 19.3 (8.7) ,0.001
Physical activity grade (mean, sD) 4.1 (1.6) 4.3 (1.5) 3.7 (1.4) 4.6 (1.5) ,0.001
Minutes walked per day (mean, sD) 73.5 (68.2)a 64.2 (52.3) 56.1 (45.8) 68.8 (55.2) 0.001
Notes: aexcluded vs included patients. balone vs professional caregiver. cBasic literacy vs completed university.
Abbreviations: BDI, Beck Depression Inventory; BMI, body mass index; BODEx, Body mass index, airflow Obstruction, Dyspnea and Exacerbations index; CAT, COPD 
assessment Test; COPD, chronic obstructive pulmonary disease; eQ-5D, euroQol-5 dimensions; FeV1, forced expiratory volume in 1 second; FVC, forced vital capacity; 
mMRC, Modified Medical Research Council scale; MMSE, mini-mental state examination; SD, standard deviation.





(MCI; Figure 1). Patients with MMSE scores ,27 were 
older, had a lower level of formal education, had heavier 
smoking exposure, presented more respiratory symptoms, 
had more frequently domiciliary oxygen, suffered a higher 
number of and more severe exacerbations during the previ-
ous year, and had a greater comorbidity burden. In addition, 
higher levels of depression, more suicidal ideation, poorer 
quality of life, and less physical activity were more frequent 
in cognitively impaired patients.
Factors associated with the presence of 
cognitive impairment
In the univariate analysis, cognitive impairment was associ-
ated with higher age, lower educational level, worse lung 
function and more severe COPD, more frequent respiratory 
symptoms and exacerbations, and oxygen therapy requirement. 
Higher comorbidity burden, more depressive symptoms, 
and more impaired health status (EQ-5D and CAT) were 
also associated with cognitive impairment. Higher levels 
of physical activity were associated with better cognitive 
function (Table 2).
In the multivariate analysis, only educational level and 
the EQ-5D social tariff were independently and significantly 
associated with cognitive impairment (Table 2). When 
the analysis was limited to the usual demographic and 
clinical variables, and the questionnaires were excluded 
from the model, the significant factors in the multivariate 
analysis were educational level, history of exacerbations, 
Figure 1 Flow diagram for the analysis.
Abbreviation: MMse, mini-mental state examination.
Table 2 Factors associated with cognitive impairment in univariate and multivariate analysis
Variable Univariate Multivariate
OR 95% CI P-value OR 95% CI P-value
age (per 5-year increment) 1.177 1.099–1.262 ,0.001
educational level
(completed university vs basic literacy)
0.160 0.080–0.310 ,0.001 0.069 0.011–0.447 0.014
Postbronchodilator FVC 0.977 0.963–0.991 0.001
Postbronchodilator FeV1 0.975 0.959–0.991 0.003
Cough 2.290 1.540–3.410 ,0.001
expectoration 1.780 1.300–2.430 ,0.001
Presence of dyspnea (yes vs no) 2.850 1.360–5.960 0.005
exacerbations in the previous year (yes vs no) 4.570 2.750–7.570 ,0.001
Oxygen therapy 3.180 1.070–9.440 0.037
BODex 1.280 1.179–1.389 ,0.001
Charlson comorbidity index 1.590 1.435–1.762 ,0.001
BDI score 1.125 1.098–1.152 ,0.001
suicide ideation 3.150 2.120–4.670 ,0.001
health status according to eQ-5D 0.799 0.742–0.860 ,0.001
social tariff eQ-5D 0.971 0.965–0.977 ,0.001 0.967 0.950–0.983 ,0.001
CaT score 1.098 1.078–1.118 ,0.001
Physical activity grade 0.648 0.587–0.715 ,0.001
Minutes walked per day 0.994 0.991–0.998 0.001
Abbreviations: BDI, Beck Depression Inventory; BODEx, Body mass index, airflow Obstruction, Dyspnea and Exacerbations index; CAT, COPD Assessment Test; CI, 
confidence interval; EQ-5D, EuroQoL-5 dimensions; FEV1, forced expiratory volume in 1 second; FVC, forced vital capacity; Or, odds ratio.




Cognition in chronic obstructive pulmonary disease
the BODEx index, and the Charlson comorbidity index 
(Table 3).
Discussion
COPD is a multicomponent inflammatory disease that 
affects physical and nonphysical functions, one of which is 
cognition. In our study, we found some degree of cognitive 
impairment in almost 40% of unselected COPD patients, as 
determined by a MMSE score ,27. Previous estimates of 
cognitive dysfunction in COPD patients ranged from 12% to 
88%, depending on the study population and the tools used 
for neuropsychological assessment.5,9 A recent study in a very 
similar population (including not only elderly patients, but 
also young patients) to ours17 found MCI in 36% of COPD 
patients after comprehensive neuropsychological testing. The 
authors reported that a MMSE score of 27 provided optimal 
maximum accuracy and a diagnostic cutoff (,27 indicated 
impairment), with 97% specificity and 73% of patients cor-
rectly classified. However, they also found that the Montreal 
Cognitive Assessment performed better as a screening test 
for detecting MCI in patients with COPD. So, this threshold 
for mild impairment is not necessarily indicative of a clini-
cally significant cognitive decline associated with functional 
impairment, but could serve as an early identification of an 
affected cognitive function.
Cognitive symptoms are core symptoms in many mental 
disorders;25 they impact on cognitive functioning, which 
deteriorates as patients get older, particularly after the age 
of 60.26 COPD patients score lower on standard cognitive 
performance tests over time, compared with individuals 
of the same age without the disease.27 One hypothesis for 
this accelerated decline in COPD patients is altered brain 
perfusion.28 Changes in brain perfusion due to hypoxemia 
in subjects with severe COPD may increase cognitive 
impairment.29 In our population, more cognitively affected 
patients were receiving domiciliary oxygen that could be a 
correlate of higher disease severity and sustained periods of 
hypoxemia. In contrast, a recent study indicated that long-
term home oxygen therapy allowed to preserve cognitive 
functions from the COPD-induced deterioration,30 so the 
role of supplemental oxygen in preventing COPD-induced 
cognitive deterioration is still controversial. Indeed, other 
factors, such as hypercapnia or oxidative stress, may also be 
involved.31 Other authors have suggested that intermittent and 
continuous hypoxia resulting from poor lung function may 
lead to transient deficits in neurotransmitter metabolism in 
the central nervous system.32–34 Several mechanisms, then, 
appear to be involved in cognitive decline in this population. 
Prospective neuroimaging studies are required to characterize 
brain changes and corresponding disturbances in cognitive 
function in these patients over time.
Cognitive impairment represents a critical health care 
burden in terms of costs.35 Individuals with MCI have a higher 
risk of developing dementia than the general population.36 
Moreover, cognitive dysfunction in COPD has been asso-
ciated with poorer outcomes and even with an increase in 
disability and mortality.8,37,38 Thus, it is essential that this 
condition is identified early in COPD patients, in order to 
Table 3 Factors associated with cognitive impairment in univariate and multivariate analysis, including only demographic and clinical 
variables
Variable Univariate Multivariate
OR 95% CI P-value OR 95% CI P-value
age (per 5-year increment) 1.177 1.099–1.262 ,0.001
educational level
(completed university vs basic literacy)
0.160 0.080–0.310 ,0.001 0.063 0.010–0.394 0.010
Postbronchodilator FVC 0.977 0.963–0.991 0.001
Postbronchodilator FeV1 0.975 0.959–0.991 0.003
Cough 2.290 1.540–3.410 ,0.001
expectoration 1.780 1.300–2.430 ,0.001
Dyspnea 2.850 1.360–5.960 0.005
exacerbations 4.570 2.750–7.570 ,0.001 11.070 1.450–84.534 0.020
Oxygen therapy 3.180 1.070–9.440 0.037
BODex 1.280 1.179–1.389 ,0.001 1.261 1.049–1.515 0.014
Charlson comorbidity index 1.590 1.435–1.762 ,0.001 1.412 1.118–1.783 0.004
suicide ideation 3.150 2.120–4.670 ,0.001
Physical activity grade 0.648 0.587–0.715 ,0.001
Minutes walked per day 0.994 0.991–0.998 0.001
Abbreviations: BODEx, Body mass index, airflow Obstruction, Dyspnea and Exacerbations index; CI, confidence interval; FEV1, forced expiratory volume in 1 second; 
FVC, forced vital capacity; Or, odds ratio.





prevent or delay progression to clinical dementia or increased 
morbidity. If the factors affecting cognition are recognized, 
cognitive impairment may be detected earlier and COPD 
patients at higher risk may be identified. In our study, the 
multivariate analysis showed that educational level and 
quality of life assessed by EQ-5D were significantly and 
independently associated with the presence of cognitive 
impairment. However, the use of health-related quality of 
life or other questionnaires is not a routine practice in most 
primary care offices, so we ran a multivariate model, discard-
ing the scores of these questionnaires and including only 
demographic and clinical variables. In this model, cognitive 
impairment was associated with exacerbations in the previous 
year, the severity of COPD measured by the BODEx index, 
and a higher comorbidity burden.
Exacerbations in COPD are of great importance. They have 
been associated with increased health care costs,39 a significant 
decline in health status,40 and substantial mortality.41 Our 
results suggest that frequent exacerbations also have nega-
tive consequences on cognitive function. This is in line with 
a previous study that investigated the cognitive function of 
COPD patients who were hospitalized following an acute 
exacerbation. These patients had significantly poorer cognitive 
function compared with control participants 3 months after 
discharge from the hospital.10 Other studies have shown that 
cognitive impairment during the exacerbation period resolves 
during periods of stability.42–44 More exacerbations and 
increased COPD severity could reflect the poorer compliance 
with medication associated with cognitive impairment.6,7 The 
systemic inflammation seen in severe COPD and during acute 
exacerbations45 may participate in neurocognitive impairment 
via a direct neurotoxic effect or by affecting cerebral athero-
sclerosis.9 A high comorbidity burden may also contribute to 
persistent brain injury: multiple concomitant diseases, such 
as cerebrovascular disease and related mechanisms, including 
endothelial dysfunction and oxidation, may lead to neuronal 
death, synaptic dysfunction, and cognitive impairment.46
All these data confirm that the cognitive impairment that 
occurs in COPD patients is associated with disease severity. 
Neuropsychiatric assessment should become a routine part of 
the diagnostic procedure for these patients, to help physicians 
grade the overall impact of COPD and determine the most 
effective treatment and strategies.
The cross-sectional design of our study limits any type 
of causal inferences, and the directionality between COPD 
and cognition remains unclear. Despite the frequent use 
of the MMSE in clinical research and practice, this tool 
for cognitive impairment detection could have missed key 
domains of cognition often affected in COPD (ie, executive 
functioning). An additional limitation of our study is the lack 
of data on our patients’ medical treatment. As treatment may 
have great impact on the symptom burden and mental health 
of the patients, such information should be collected in future 
studies. In particular, prospective studies are urgently needed 
to determine the most effective behavioral and medical 
interventions for reducing the risk of poor neurocognitive 
outcomes in patients with COPD.
Conclusion
Cognitive impairment is common in COPD and has important 
clinical implications. Early detection of cognitive decline 
is crucial, in view of its association with poorer COPD out-
comes, including increased mortality, and patients with fre-
quent exacerbations and or when the BODEx index appears 
concerning the clinician may want to ask the patient and/or 
caregivers about cognitive function. These patients may need 
more individualized educational and care interventions to 
help them manage their daily lives. Clinicians must involve 
family caregivers in the care plan of patients with severe 
COPD and cognitive deficits.
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